TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

TELA Bio, Inc.NASDAQ: TELA

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue dips below year-ago levels

Q2 FY2026 revenue of $19.29M fell 4.5% year over year, behind the +6.1% change in trailing-twelve-month revenue. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +24.7% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $79.58M (-0.9%) for the fiscal year ending Dec 2026, a slowdown from the +15.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.29M+1.2% QoQ
Last fiscal yearDec 2025
$80.28M+15.8% YoY
LTMJun 2026
$79.91M+6.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.5%-3.2%+1.3 pp
1 year+15.8%-0.9%-16.7 pp
3-year CAGR+24.7%+6.2%-18.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
80.28M USD
Year-over-year change
+15.8%
4-year CAGR
+28.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 revenue of $79.91M is the highest of the 9 companies compared; the peer median is $1.85M.
  • Its year-over-year change of +6.1% is the 4th highest of 8, against a peer median of -42.9%.
  • Over three fiscal years its annual growth of +24.7% compares with a peer median of -8.2%.
TELA Competitors Peer median
Revenue for TELA and competitors
Company Period LTM YoY 3-year CAGR
TELATELA Bio, Inc.LTM Jun 2026$79.91M +6.1%+24.7%
CUECue Biopharma, Inc.LTM Mar 2026$32.73M +309.6%+180.5%
SRTSSensus Healthcare, Inc.LTM Mar 2026$22.53M -42.9%-14.9%
MDAISpectral AI, Inc.LTM Mar 2026$16.7M -44.3%-8.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$2.29M ——
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.41M +2148.9%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$333.14K +95.8%—
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 -100.0%—
EQEquillium, Inc.LTM Mar 2026$0 -100.0%—
Peer median (excluding TELA) $1.85M-42.9%-8.2%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.46M41.42M58.45M69.3M80.28M
Cost of Revenue10.65M14.37M18.34M22.81M25.93M
Gross Profit18.81M27.04M40.11M46.49M54.34M
Gross Margin63.9%65.3%68.6%67.1%67.7%
Research & Development6.74M8.94M9.62M8.81M9.22M
Selling, General & Admin41.52M57.11M74.57M79.37M78.88M
Operating Expenses48.26M66.05M84.19M80.6M88.1M
Depreciation & Amortization535K1.19M808K1.01M1.01M
EBITDA(29.14M)(39.06M)(40.63M)(31.68M)(32.35M)
EBITDA Margin-98.9%-94.3%-69.5%-45.7%-40.3%
Operating Income(29.45M)(39.01M)(44.08M)(34.12M)(33.76M)
Operating Margin-100.0%-94.2%-75.4%-49.2%-42.0%
Interest Income00000
Interest Expense3.6M4.05M5.22M5.29M5.25M
Other Income / Expenses(3.83M)(5.29M)(2.59M)(3.87M)(4.85M)
Income Before Tax(33.28M)(44.3M)(46.66M)(37.99M)(38.6M)
Pre-Tax Margin-112.9%-106.9%-79.8%-54.8%-48.1%
Income Tax Expense000(144K)230K
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Net Margin-112.9%-106.9%-79.8%-54.6%-48.4%
EPS (Basic)(2.30)(2.73)(2.04)(1.33)(0.83)
EPS (Diluted)(2.30)(2.73)(2.04)(1.33)(0.83)
Weighted Avg Shares14.47M16.27M22.87M28.53M46.95M
Weighted Avg Shares (Diluted)14.47M16.27M22.87M28.53M46.95M

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.